Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine as adjunctive therapy for refractory major depressive disorder
IRCT20250215064730N1Phase 3Completed
- Sponsor
- Kashan University of Medical Sciences
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ketamine in major depressive disorder (MDD), sponsored by Kashan University of Medical Sciences. Started Aug 2023; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20250215064730N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250215064730N1.